Acclarent breathes in $26m for sinus treatment
This article was originally published in Clinica
Menlo Park, California-based Acclarent is to ramp up commercialisation of its balloon catheter-based sinus treatment, Balloon Sinuplasty, after receiving $26m in new capital. The funds came from Acclarent's existing shareholders as well as new investor Johnson & Johnson. Part of the proceeds will also go towards advancing development of Acclarent's pipeline products and clinical studies.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.